Who are acid mycophenolic (Myfortic)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate, Elidel, SIROLIMUS, Rapamune, Cellcept, Prograf.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acid-mycophenolic-myfortic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

acid mycophenolic (Myfortic) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

acid mycophenolic (Myfortic) (acid mycophenolic (Myfortic)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: immunosuppressant. Area: Immunology.

phase 3 immunosuppressant inosine monophosphate dehydrogenase (IMPDH) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

acid mycophenolic (Myfortic) (acid mycophenolic (Myfortic)) — Assistance Publique - Hôpitaux de Paris. Acid mycophenolic inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine nucleotides.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
acid mycophenolic (Myfortic) TARGET	acid mycophenolic (Myfortic)	Assistance Publique - Hôpitaux de Paris	phase 3	immunosuppressant	inosine monophosphate dehydrogenase (IMPDH)
Mycophenolate	MYCOPHENOLIC ACID	Novartis	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	2004-01-01
Elidel	PIMECROLIMUS	Bausch Health	marketed	Calcineurin Inhibitor Immunosuppressant [EPC]	Peptidyl-prolyl cis-trans isomerase FKBP1A	2001-01-01
SIROLIMUS	SIROLIMUS		marketed	mTOR Inhibitor Immunosuppressant [EPC]	mTOR	1999-01-01
Rapamune	sirolimus	Pfizer	marketed	mTOR Inhibitor Immunosuppressant [EPC]	Serine/threonine-protein kinase mTOR	1999-01-01
Cellcept	MYCOPHENOLATE MOFETIL	Roche Palo	marketed	Antimetabolite Immunosuppressant	Inosine-5'-monophosphate dehydrogenase 2	1995-01-01
Prograf	TACROLIMUS	Astellas Pharma	marketed	Calcineurin Inhibitor Immunosuppressant	Interferon gamma	1994-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-05-30 — Prograf · 12403095 · Formulation · US
2028-05-30 — Prograf · 11419823 · Formulation · US
2028-05-30 — Prograf · 9549918 · Formulation · US
2028-05-30 — Prograf · 11123331 · Method of Use · US
2028-05-30 — Prograf · 11110081 · Method of Use · US
2028-05-30 — Prograf · 12083103 · Method of Use · US
2028-05-30 — Prograf · 10864199 · Method of Use · US
2028-05-30 — Prograf · 10166190 · Formulation · US
2028-08-30 — Prograf · 8685998 · Formulation · US
2028-08-30 — Prograf · 8664239 · Method of Use · US
2029-02-14 — Rapamune · 8911786 · Formulation · US
2030-04-15 — Rapamune · 10206887 · Formulation · US
2036-03-05 — Rapamune · 10705070 · Formulation · US
2036-03-05 — Rapamune · 12061183 · Formulation · US
2036-06-29 — Rapamune · 12133844 · Method of Use · US
2036-06-29 — Rapamune · 10973806 · Method of Use · US
2039-08-16 — Cellcept · 12097285 · Formulation · US
2039-08-16 — Cellcept · 11931455 · Formulation · US
2039-08-16 — Cellcept · 12226526 · Formulation · US
2039-08-16 — Cellcept · 12097284 · Formulation · US
2039-08-16 — Cellcept · 12194143 · Formulation · US
2040-10-28 — Rapamune · 11497737 · Formulation · US

Sponsor landscape (immunosuppressant class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
DH Bio Co., Ltd. · 1 drug in this class
Glenmark Pharmaceuticals Ltd. India · 1 drug in this class
Palvella Therapeutics, Inc. · 1 drug in this class
Pfizer · 1 drug in this class
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · 1 drug in this class
University of California, San Francisco · 1 drug in this class
Vanderbilt-Ingram Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). acid mycophenolic (Myfortic) — Competitive Intelligence Brief. https://druglandscape.com/ci/acid-mycophenolic-myfortic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab